An analysis in Stat shared recent findings from the American Association for the Advancement of Science conference that indicate liraglutide–the glucagon-like peptide-1 (GLP-1) medication used for weight loss—significantly reduced opioid cravings for patients in a small randomized controlled trial. The 20 patients used anti-obesity drugs for opioid use disorder for 3 weeks, and those using liraglutide experienced a 40% reduction in opioid cravings, even when the lowest dose was used. Ramp up recovery: Buprenorphine is the …
Read More